(Reuters) - The tiny biotech company, which is developing the treatment from a toxin found in the pufferfish, said Canada's health watchdog sent it a "No Objection Letter" to conduct a Phase 3 clinical trial on cancer pain for its lead product, Tectin.
The multi-centre, randomized, double-blind, and placebo-controlled trial will include about 120 patients with moderate to severe cancer-related pain.
Read more at Reuters.com Government Filings News
The multi-centre, randomized, double-blind, and placebo-controlled trial will include about 120 patients with moderate to severe cancer-related pain.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment